Azenta and Frenova Partner to Boost Genomic Research in Kidney and Metabolic Diseases

Azenta and Frenova’s Partnership to Advance Genomic Research in Nephrology

Announcement

Frenova, a division of Fresenius Nephronomics and Medical Care, a renal precision medicine company, and Azenta Inc. entered into a partnership to head start with data generation for Frenova’s transitional myreason® genomics research program and genomic sequencing. These valuable partnerships focus on accelerating technology to improve the understanding of cardio-kidney-metabolic diseases and drive advancements in precision medicines for the global population of patients.

MyReason® and Nephronomics

The MyReason research program is an excellent initiative introduced to discover insights into the genetic mechanisms focusing on kidney diseases. More than 35,000 participants are hired in the program and enabled to provide biospecimens, and further, the aim is to register 50,000 participants in the next two years. The nephronomics has marketing rights to the myreason dataset, which assists the nephronomics atlas, an exploratory resource to genomic cardio-kidney-metabolic (CKM) disease data and clinicals.

Nephronomics is sharply focusing on the development of targeted therapeutics and redesigning the CKM disease care via precision medicine insights. By elevating machine learning (ML) and artificial intelligence (AI) models trained on this robust dataset, nephronomics addresses therapeutic targets, subtypes of disease, and safety genetic variants.

Role of Azenta

Azenta will contribute to this collaboration by serving genomic sequencing across GENEWIZ and managing long-term sample storage within its worldwide biorepository network. With many years of experience in sample management solutions and multiomics analysis, Azenta is well-positioned to enable remarkable solutions for complicated research programs.

Views and Statements

President of GENEWIZ, Ginger Zhou, said, “We are excited to collaborate with frenova and nephronomics and support the myreason research program.”

President of Frenova, Jan Walter, said, “This broad genome sequencing initiative symbolizes a vital milestone in our journey to form the most reliable genotype-phenotype database for CKM patients. We are excited to partner with Nephronomics on the discussion of the nephronomics atlas, that commit to uncover remarkable insights that will transform patient care.

Founder of nephronomics, James Sietstra, said, “The expertise in nephrology and Frenova’s Myreason initiative, merged with Azenta’s innovative genomic sequencing and sample management solutions, shows significant cornerstones of the nephronomics atlas.” Further, “This robust partnership will allow us to explore new insights that will advance scientific understanding also introduce new ways to initiate effective diagnostics and therapies in the cardio-kidney-metabolic space.”